Article
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer research - 15 Mar 2008
Jhawer Minaxi, Goel Sanjay, Wilson Andrew J, Montagna Cristina, Ling Yi-He, Byun Do-Sun, Nasser Shannon, Arango Diego, Shin Joongho, Klampfer Lidija, Augenlicht Leonard H, Perez-Soler Roman, Soler Roman Perez, Mariadason John M
Abstract excerpt
Cetuximab is a monoclonal antibody that targets the human epidermal growth factor receptor (EGFR). Although approved for use in EGFR-overexpressing advanced colorectal cancer, recent studies have shown a lack of association between EGFR overexpression and cetuximab response, requiring the identification of novel biomarkers predictive of response to this agent. To do so, 22 colon cancer cell lines were screened...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.